Rutgers Cancer Institute | Strategic Alliance Partners

July 13, 2022

A world-class team of researchers assembled and led by Rutgers Cancer Institute of New Jersey and its Deputy Director and Chief Scientific Officer Eileen White, PhD, has been awarded a $25 million Cancer Grand Challenges grant to tackle the condition of cancer cachexia.

July 08, 2022

The Rutgers Board of Governors has named Rutgers Cancer Institute of New Jersey Deputy Director Eileen White, PhD, the Board of Governors Professor of Molecular Biology and Biochemistry at the Rutgers School of Arts and Sciences for her contributions to science and leadership in the fields of apoptosis, autophagy and cancer metabolism.

July 05, 2022

Results from a study of individuals living with HIV show treatment of a precancerous condition known high-grade squamous intraepithelial lesions of the anus cuts the risk of developing anal cancer in this population by more than half.

June 30, 2022

Ronald D. Ennis, MD, shares how radiotherapy is an excellent treatment for many men with prostate cancer, providing a minimally-invasive treatment with low adverse effect risks.

June 19, 2022

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

June 16, 2022

Mridula George, MD, discusses the background of the phase 3 DESTINY-Breast04 trial in breast cancer.

June 16, 2022

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.

June 08, 2022

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Ira Braunschweig, MD, as chief, Section of Transplant and Cell Therapy at Rutgers Cancer Institute, chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital.

May 26, 2022

Sanjay Goel, MD, MS, discusses the need for diverse representation in clinical trials.

May 20, 2022

Denalee O'Malley, PhD, sheds light on racial and ethnic disparities in colorectal cancer screening, and strategies that can be used to address existing barriers in the clinic and beyond.

May 13, 2022

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

May 12, 2022

With the aid of a $3.5 million National Institutes of Health grant, investigators from Rutgers Cancer Institute of New Jersey, along with Holden Cancer Center at the University of Iowa, and the University of Texas MD Anderson Cancer Center, are collaborating on a project to address lung cancer screening disparities among individuals with a history of heavy smoking

April 01, 2022

Mridula George, MD, discusses efforts to address unmet needs in HER2-low breast cancer.

February 16, 2022

Rutgers Cancer Institute of New Jersey has named Sanjay Goel, MD, MS as director of its Phase I/Investigational Therapeutics Program.

February 10, 2022

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

January 12, 2022

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

December 31, 2021

Despite advances in treatments for T-cell acute lymphoblastic leukemia, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of the disease, as well as the need to discover new targeted therapeutic approaches and treatment resistance

December 28, 2021

Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.

December 17, 2021

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

December 16, 2021

Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.